Order Article Reprints

Zakowiecki D, Edinger P, Papaioannou M, Wagner M, Hess T, Paszkowska J, Staniszewska M, Myslitska D, Smolenski M, Dobosz J, et al. Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban. Pharmaceutics. 2024; 16(11):1485. https://doi.org/10.3390/pharmaceutics16111485

Zakowiecki, Daniel, Peter Edinger, Markos Papaioannou, Michael Wagner, Tobias Hess, Jadwiga Paszkowska, Marcela Staniszewska, Daria Myslitska, Michal Smolenski, Justyna Dobosz, and et al. 2024. "Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban" Pharmaceutics 16, no. 11: 1485. https://doi.org/10.3390/pharmaceutics16111485

Zakowiecki, D., Edinger, P., Papaioannou, M., Wagner, M., Hess, T., Paszkowska, J., Staniszewska, M., Myslitska, D., Smolenski, M., Dobosz, J., Garbacz, G., & Haznar Garbacz, D. (2024). Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban. Pharmaceutics, 16(11), 1485. https://doi.org/10.3390/pharmaceutics16111485